Literature DB >> 22556319

Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia?

Primrose P Freestone1, Robert A Hirst2, Sara M Sandrini1, Fathima Sharaff1, Helen Fry1, Stefan Hyman3, Chris O'Callaghan4.   

Abstract

BACKGROUND: Ventilated patients receiving intensive care are at significant risk of acquiring a ventilator-associated pneumonia that is associated with significant morbidity and mortality. Despite intensive research, it is still unclear why Pseudomonas aeruginosa, a microbe that rarely causes pneumonia outside of intensive care, is responsible for so many of these infections.
METHODS: We investigated whether medications frequently prescribed to patients in the ICU, the catecholamine inotropes, were affecting the growth and virulence of P aeruginosa . Effects of clinically attainable concentrations of inotropes on P aeruginosa pathogenicity were explored using in vitro growth and virulence assays and an ex vivo model of infection using ciliated human respiratory epithelium.
RESULTS: We found that inotropes were potent stimulators of P aeruginosa growth, producing upto 50-fold increases in bacterial numbers via a mechanism involving inotrope delivery of transferrin-ron,internalization of the inotrope, and upregulation of the key pseudomonal siderophore pyoverdine.Inotropes also markedly increased biofilm formation on endotracheal tubing and enhanced the biofilm production and toxicity of P aeruginosa in its interaction with respiratory epithelium.Importantly, catecholamine inotropes also facilitated the rapid recovery of P aeruginosa from tobramycin antibiotic challenge. We also tested out the effect of the inotropes vasopressin and phenylephrine on the growth and virulence of P aeruginosa and found that, in contrast to the catecholamines,these drugs had no stimulatory effect.
CONCLUSIONS: Collectively, our results suggest that catecholamine inotrope-bacterial interactions may be an unexpected contributory factor to the development of P aeruginosa -ventilator-associated pneumonia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22556319     DOI: 10.1378/chest.11-2614

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

Review 1.  Homeostasis and its disruption in the lung microbiome.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 2.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 3.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 4.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

5.  Intraalveolar Catecholamines and the Human Lung Microbiome.

Authors:  Robert P Dickson; John R Erb-Downward; Hallie C Prescott; Fernando J Martinez; Jeffrey L Curtis; Vibha N Lama; Gary B Huffnagle
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

6.  Ciliated Epithelial Cell Differentiation at Air-Liquid Interface Using Commercially Available Culture Media.

Authors:  Dani Do Hyang Lee; Alina Petris; Robert E Hynds; Christopher O'Callaghan
Journal:  Methods Mol Biol       Date:  2020

7.  The Lung Microbiome and ARDS. It Is Time to Broaden the Model.

Authors:  Robert P Dickson
Journal:  Am J Respir Crit Care Med       Date:  2018-03-01       Impact factor: 21.405

Review 8.  Methods in Lung Microbiome Research.

Authors:  Sharon M Carney; Jose C Clemente; Michael J Cox; Robert P Dickson; Yvonne J Huang; Georgios D Kitsios; Kirsten M Kloepfer; Janice M Leung; Tricia D LeVan; Philip L Molyneaux; Bethany B Moore; David N O'Dwyer; Leopoldo N Segal; Stavros Garantziotis
Journal:  Am J Respir Cell Mol Biol       Date:  2020-03       Impact factor: 6.914

Review 9.  Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum.

Authors:  Davide Tommaso Andreis; Mervyn Singer
Journal:  Intensive Care Med       Date:  2016-02-12       Impact factor: 17.440

10.  Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Authors:  Paul G Ambrose; Brian D VanScoy; John Adams; Steven Fikes; Justin C Bader; Sujata M Bhavnani; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.